Legal status in the United States

Is NAD+ legal?

Read at FDA, DEA and WADAPublished by PepVault

NAD+ has no FDA-approved product, is not a federally controlled substance, and is not named on WADA’s Prohibited List, as of November 18, 2026.

NAD+ at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved
CompoundingUnder FDA evaluation (503A category 1)
DEA scheduleNot controlled
Sport (WADA)Not named on the list

FDA approval

NAD+ has no FDA-approved drug: Drugs@FDA lists no application for it.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA lists nicotinamide adenine dinucleotide (NAD) in 503A category 1, bulk substances under evaluation, on its list updated May 14, 2026; it is not on the 503B bulks list.

The source: “Nicotinamide Adenine Dinucleotide (NAD)”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

The 2026 Prohibited List doesn’t name NAD+. Separately, its M2.2 bans intravenous infusions or injections of “more than a total of 100 mL per 12-hour period”, whatever they hold, outside hospital care.

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about NAD+ in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is NAD+ FDA approved?

    NAD+ has no FDA-approved drug: Drugs@FDA lists no application for it.

  • Is NAD+ a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is NAD+ banned in sport?

    The 2026 Prohibited List doesn’t name NAD+. Separately, its M2.2 bans intravenous infusions or injections of “more than a total of 100 mL per 12-hour period”, whatever they hold, outside hospital care.

  • What does FDA say about compounding NAD+?

    FDA lists nicotinamide adenine dinucleotide (NAD) in 503A category 1, bulk substances under evaluation, on its list updated May 14, 2026; it is not on the 503B bulks list.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo